David J. Cohen

David J. Cohen

Auto-generated profile, based on publicly available information

David J. Cohen

Cardiovascular Research Foundation, New York, New York, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2021 in European Heart Journal
Verified
Journal Article
Closed access
VCVARC-3 WRITING COMMITTEE
VARC-3 WRITING COMMITTEE
PGPhilippe Généreux
Philippe Généreux
NPNicolo Piazza
Nicolo Piazza
MAMaria C Alu
Maria C Alu
TNTamim Nazif
Tamim Nazif
MLMartin B Leon
Martin B Leon
Aims : The Valve Academic Research Consortium (VARC), founded in 2010, was intended to (i) identify appropriate clinical endpoints and (ii) standardize definitions of these endpoints for transcatheter and surgical aortic valve clinical trials. Rapid evolution of the field, including the emergence of new complications, expanding clinical indications, and novel therapy strategies have mandated further refinement and expansion of these definitions to ensure clinical relevance. This document provides an update of the most appropriate clinical endpoint definitions to be used in the conduct of transcatheter and surgical aortic valve clinical research.Methods and results : Several years after the publication of the VARC-2 manuscript, an in-person meeting was held involving over 50 independent clinical experts representing several professional societies, academic research organizations, the US Food and Drug Administration (FDA), and industry representatives to (i) evaluate utilization of VARC endpoint definitions in clinical research, (ii) discuss the scope of this focused update, and (iii) review and revise specific clinical endpoint definitions. A writing committee of independent experts was convened and subsequently met to further address outstanding issues. There were ongoing discussions with FDA and many experts to develop a new classification schema for bioprosthetic valve dysfunction and failure. Overall, this multi-disciplinary process has resulted in important recommendations for data reporting, clinical research methods, and updated endpoint definitions. New definitions or modifications of existing definitions are being proposed for repeat hospitalizations, access site-related complications, bleeding events, conduction disturbances, cardiac structural complications, and bioprosthetic valve dysfunction and failure (including valve leaflet thickening and thrombosis). A more granular 5-class grading scheme for paravalvular regurgitation (PVR) is being proposed to help refine the assessment of PVR. Finally, more specific recommendations on quality-of-life assessments have been included, which have been targeted to specific clinical study designs.Conclusions : Acknowledging the dynamic and evolving nature of less-invasive aortic valve therapies, further refinements of clinical research processes are required. The adoption of these updated and newly proposed VARC-3 endpoints and definitions will ensure homogenous event reporting, accurate adjudication, and appropriate comparisons of clinical research studies involving devices and new therapeutic strategies.

2 February 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
LYLuiz F. Ybarra
Luiz F. Ybarra
SRStéphane Rinfret
Stéphane Rinfret
EBEmmanouil Brilakis
Emmanouil Brilakis
DKDimitri Karmpaliotis
Dimitri Karmpaliotis
LALorenzo Azzalini
Lorenzo Azzalini
OCOn behalf of the Chronic Total Occlusion Academic Research Consortium
On behalf of the Chronic Total Occlusion Academic Research Consortium
Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention has developed into its own subspecialty of interventional cardiology. Dedicated terminology, techniques, devices, courses, and training programs have enabled progressive advancements. However, only a few randomized trials have been performed to evaluate the safety and efficacy of CTO percutaneous coronary intervention. Moreover, several published observational studies have shown conflicting data. Part of the paucity of clinical data stems from the fact that prior studies have been suboptimally designed and performed. The absence of standardized end points and the discrepancy in definitions also prevent consistency and uniform interpretability of reported results in CTO intervention. To standardize the field, we therefore assembled a broad consortium comprising academicians, practicing physicians, researchers, medical society representatives, and regulators (US Food and Drug Administration) to develop methods, end points, biomarkers, parameters, data, materials, processes, procedures, evaluations, tools, and techniques for CTO interventions. This article summarizes the effort and is organized into 3 sections: key elements and procedural definitions, end point definitions, and clinical trial design principles. The Chronic Total Occlusion Academic Research Consortium is a first step toward improved comparability and interpretability of study results, supplying an increasingly growing body of CTO percutaneous coronary intervention evidence.

4 October 2023 in JACC
Verified
Journal Article
Open access
RHRebecca T Hahn
Rebecca T Hahn
MLMatthew K. Lawlor
Matthew K. Lawlor
CDCharles J. Davidson
Charles J. Davidson
VBVinay Badhwar
Vinay Badhwar
ASAnna Sannino
Anna Sannino
GSGregg Stone
Gregg Stone
Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.

1 October 2020 in European Heart Journal
Verified
Journal Article
Closed access
UBUsman Baber
Usman Baber
GDGeorge Dangas
George Dangas
Dominick Joseph AngiolilloDominick Joseph Angiolillo
Dominick Joseph Angiolillo
DCDavid Joel Cohen
David Joel Cohen
SSSamin Kumar Sharma
Samin Kumar Sharma
RMRoxana Mehran
Roxana Mehran
Aims : The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without non-ST elevation acute coronary syndromes (NSTE-ACS) among patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods and results : We conducted a pre-specified subgroup analysis of The Ticagrelor With Aspirin or Alone in High Risk Patients After Coronary Intervention (TWILIGHT) trial, which enrolled 9006 patients with high-risk features undergoing PCI with DES. After 3 months of dual antiplatelet therapy (DAPT) with ticagrelor plus aspirin, 7119 adherent and event-free patients were randomized in a double-blind manner to ticagrelor plus placebo versus ticagrelor plus aspirin for 12 months. The primary outcome was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding while the composite of all-cause death, myocardial infarction (MI), or stroke was the key secondary outcome. Among patients with NSTE-ACS (n = 4614), ticagrelor monotherapy reduced BARC 2, 3, or 5 bleeding by 53% [3.6% vs. 7.6%; hazard ratio (HR) 0.47; 95% confidence interval (CI) 0.36–0.61; P < 0.001) and in stable patients (n = 2503) by 24% (4.8% vs. 6.2%; HR 0.76; 95% CI 0.54–1.06; P = 0.11; nominal P int = 0.03). Rates of all-cause death, MI, or stroke among those with (4.3% vs. 4.4%; HR 0.97; 95% CI 0.74–1.28; P = 0.84) and without (3.1% vs. 3.2%; HR 0.96; 95% CI 0.61–1.49; P = 0.85) NSTE-ACS were similar between treatment arms irrespective of clinical presentation (P int = 0.96). Conclusion : Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS. Trial registration: Clinicaltrials.gov identifier: NCT02270242.

28 October 2024 in JACC
Verified
Journal Article
Closed access
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
SESammy Elmariah
Sammy Elmariah
ESErnest Spitzer
Ernest Spitzer
PPPhilippe Pibarot
Philippe Pibarot
TNTamim M. Nazif
Tamim M. Nazif
MLMartin B. Leon
Martin B. Leon

1 June 2020 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
NBNeel M. Butala
Neel M. Butala
MCMabel Chung
Mabel Chung
ESEric A. Secemsky
Eric A. Secemsky
PMPratik Manandhar
Pratik Manandhar
GMGuillaume Marquis-Gravel
Guillaume Marquis-Gravel
DCDavid J. Cohen
David J. Cohen